Meveol : orphan drug status granted by the FDA for the treatment of cystic fibrosis.

LYON (France) December, 8th : Alaxia is glad to announce that its medicinal product candidate Hypothiocyanite (OSCN) / Lactoferrin developed under the brand name Meveol, received Orphan drug designation for the treatment of cystic fibrosis (CF) by the US FDA (Food and Drug Administration). LYON (France) December, 8th : Alaxia is glad to announce that its medicinal product candidate Hypothiocyanite (OSCN) / Lactoferrin developed under the brand name Meveol, received Orphan drug designation for the treatment of cystic fibrosis (CF) by the US FDA (Food and Drug Administration).
-->